Clinical Trial

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma. This study will include two arms: Cohort A (HDM2005 + R-GemOx) will enroll participants with relapsed/refractory DLBCL. Cohort B (HDM2005 + R-CHP) will enroll participants with untreated DLBCL. The study will consist of two parts: dose-escalation part and dose-expansion part.
Trial Details
NCT Number NCT07124936
Lead Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions Diffuse Large B Cell Lymphoma (DLBCL)
Enrollment 97 participants
Start Date 2025-07-30
Primary Completion 2027-10-26 (estimated)
Study Completion 2029-10-25 (estimated)
Updated on ClinicalTrials.gov 2025-08-15